Global Kaposi Sarcoma Market 2017-2021
出 版 商：Technavio
出版日期：2017/05/03
頁 數：70頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
About Kaposi Sarcoma
Kaposi sarcoma is a multicentral tumor. The tumor is caused by Kaposi sarcoma-associated herpesvirus (KSHV) also known as human herpesvirus 8 (HHV8). It can occur as endemic, classic, epidemic, and iatrogenic forms. Epidemic or acquired immune deficiency syndrome (AIDS)-associated form of treatment is one of the most prevalent types followed in the treatment of Kaposi sarcoma globally. The diagnosis is done by biopsy, and major treatment types include chemotherapy, HAART, and immunotherapy. HAART is the most common type of treatment due to a high prevalence rate of AIDS-associated Kaposi sarcoma.
Technavio’s analysts forecast the global Kaposi sarcoma market to grow at a CAGR of 2.46% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global Kaposi sarcoma market for 2017-2021. To calculate the market size, the report considers the sales of both generic as well as branded drugs.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Kaposi Sarcoma Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Bristol-Myers Squibb
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Merck
Other prominent vendors
‧ Eli Lilly
‧ Pfizer
Market driver
‧ Rising number of organ transplants
‧ For a full, detailed list, view our report
Market challenge
‧ High cost of treatment
‧ For a full, detailed list, view our report
Market trend
‧ Increasing consolidation in the cancer treatment market
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Kaposi sarcoma is a multicentral tumor. The tumor is caused by Kaposi sarcoma-associated herpesvirus (KSHV) also known as human herpesvirus 8 (HHV8). It can occur as endemic, classic, epidemic, and iatrogenic forms. Epidemic or acquired immune deficiency syndrome (AIDS)-associated form of treatment is one of the most prevalent types followed in the treatment of Kaposi sarcoma globally. The diagnosis is done by biopsy, and major treatment types include chemotherapy, HAART, and immunotherapy. HAART is the most common type of treatment due to a high prevalence rate of AIDS-associated Kaposi sarcoma.
Technavio’s analysts forecast the global Kaposi sarcoma market to grow at a CAGR of 2.46% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global Kaposi sarcoma market for 2017-2021. To calculate the market size, the report considers the sales of both generic as well as branded drugs.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Kaposi Sarcoma Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Bristol-Myers Squibb
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Merck
Other prominent vendors
‧ Eli Lilly
‧ Pfizer
Market driver
‧ Rising number of organ transplants
‧ For a full, detailed list, view our report
Market challenge
‧ High cost of treatment
‧ For a full, detailed list, view our report
Market trend
‧ Increasing consolidation in the cancer treatment market
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: An overview of Kaposi sarcoma
PART 06: Market landscape
‧ Market overview
‧ Market size and forecast
‧ Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by type of treatment
‧ HAART
‧ Chemotherapy
‧ Immunotherapy
PART 09: Geographical segmentation
‧ Kaposi sarcoma market in Americas
‧ Kaposi sarcoma market in EMEA
‧ Kaposi sarcoma market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 12: Market trends
‧ Increasing consolidation in the cancer treatment market
‧ Emphasis on combination therapy
‧ Application of Kaposi sarcoma-specific treatment (local treatment)
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ Bristol-Myers Squibb
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Merck
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Types of Kaposi sarcoma
Exhibit 02: Treatment overview for Kaposi sarcoma
Exhibit 03: Global Kaposi sarcoma market snapshot
Exhibit 04: Global Kaposi sarcoma market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global Kaposi sarcoma market
Exhibit 06: Five forces analysis
Exhibit 07: Key pipeline candidates by sponsors/collaborators
Exhibit 08: Pipeline analysis
Exhibit 09: Segmentation of global Kaposi sarcoma market by type of treatment
Exhibit 10: Combination antiretroviral therapy (ART): Common inclusions
Exhibit 11: Global Kaposi sarcoma HAART therapy market 2016-2021 ($ millions)
Exhibit 12: Change in HIV/AIDS population 2010-2015
Exhibit 13: Major types of chemotherapy
Exhibit 14: Global Kaposi sarcoma chemotherapy market 2016-2021 ($ millions)
Exhibit 15: Advantages and disadvantages of chemotherapy
Exhibit 16: Global Kaposi sarcoma immunotherapy market 2016-2021 ($ millions)
Exhibit 17: Segmentation of global Kaposi sarcoma market based on geography 2016 and 2021
Exhibit 18: Kaposi sarcoma market revenue by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: Kaposi sarcoma market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Kaposi sarcoma market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Kaposi sarcoma market in APAC 2016-2021 ($ millions)
Exhibit 25: Percentage distribution of organ transplants in US 1988-2016
Exhibit 26: Total global population living with HIV/AIDS (million)
Exhibit 27: Global number of people living with and died due to AIDS/HIV 2014-2015 (million)
Exhibit 28: Kaposi sarcoma: Before and after the AIDS epidemic in US
Exhibit 29: Competitive analysis of global Kaposi sarcoma market
Exhibit 30: Bristol-Myers Squibb: Key highlights
Exhibit 31: Bristol-Myers Squibb: Strength assessment
Exhibit 32: Bristol-Myers Squibb: Strategy assessment
Exhibit 33: Bristol-Myers Squibb: Opportunity assessment
Exhibit 34: GlaxoSmithKline: Key highlights
Exhibit 35: GlaxoSmithKline: Strength assessment
Exhibit 36: GlaxoSmithKline: Strategy assessment
Exhibit 37: GlaxoSmithKline: Opportunity assessment
Exhibit 38: Johnson & Johnson: Key highlights
Exhibit 39: Johnson & Johnson: Strength assessment
Exhibit 40: Johnson & Johnson: Strategy assessment
Exhibit 41: Johnson & Johnson: Opportunity assessment
Exhibit 42: Merck: Key highlights
Exhibit 43: Merck: Strength assessment
Exhibit 44: Merck Strategy assessment
Exhibit 45: Merck: Opportunity assessment
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: An overview of Kaposi sarcoma
PART 06: Market landscape
‧ Market overview
‧ Market size and forecast
‧ Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by type of treatment
‧ HAART
‧ Chemotherapy
‧ Immunotherapy
PART 09: Geographical segmentation
‧ Kaposi sarcoma market in Americas
‧ Kaposi sarcoma market in EMEA
‧ Kaposi sarcoma market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 12: Market trends
‧ Increasing consolidation in the cancer treatment market
‧ Emphasis on combination therapy
‧ Application of Kaposi sarcoma-specific treatment (local treatment)
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ Bristol-Myers Squibb
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Merck
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Types of Kaposi sarcoma
Exhibit 02: Treatment overview for Kaposi sarcoma
Exhibit 03: Global Kaposi sarcoma market snapshot
Exhibit 04: Global Kaposi sarcoma market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global Kaposi sarcoma market
Exhibit 06: Five forces analysis
Exhibit 07: Key pipeline candidates by sponsors/collaborators
Exhibit 08: Pipeline analysis
Exhibit 09: Segmentation of global Kaposi sarcoma market by type of treatment
Exhibit 10: Combination antiretroviral therapy (ART): Common inclusions
Exhibit 11: Global Kaposi sarcoma HAART therapy market 2016-2021 ($ millions)
Exhibit 12: Change in HIV/AIDS population 2010-2015
Exhibit 13: Major types of chemotherapy
Exhibit 14: Global Kaposi sarcoma chemotherapy market 2016-2021 ($ millions)
Exhibit 15: Advantages and disadvantages of chemotherapy
Exhibit 16: Global Kaposi sarcoma immunotherapy market 2016-2021 ($ millions)
Exhibit 17: Segmentation of global Kaposi sarcoma market based on geography 2016 and 2021
Exhibit 18: Kaposi sarcoma market revenue by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: Kaposi sarcoma market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Kaposi sarcoma market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Kaposi sarcoma market in APAC 2016-2021 ($ millions)
Exhibit 25: Percentage distribution of organ transplants in US 1988-2016
Exhibit 26: Total global population living with HIV/AIDS (million)
Exhibit 27: Global number of people living with and died due to AIDS/HIV 2014-2015 (million)
Exhibit 28: Kaposi sarcoma: Before and after the AIDS epidemic in US
Exhibit 29: Competitive analysis of global Kaposi sarcoma market
Exhibit 30: Bristol-Myers Squibb: Key highlights
Exhibit 31: Bristol-Myers Squibb: Strength assessment
Exhibit 32: Bristol-Myers Squibb: Strategy assessment
Exhibit 33: Bristol-Myers Squibb: Opportunity assessment
Exhibit 34: GlaxoSmithKline: Key highlights
Exhibit 35: GlaxoSmithKline: Strength assessment
Exhibit 36: GlaxoSmithKline: Strategy assessment
Exhibit 37: GlaxoSmithKline: Opportunity assessment
Exhibit 38: Johnson & Johnson: Key highlights
Exhibit 39: Johnson & Johnson: Strength assessment
Exhibit 40: Johnson & Johnson: Strategy assessment
Exhibit 41: Johnson & Johnson: Opportunity assessment
Exhibit 42: Merck: Key highlights
Exhibit 43: Merck: Strength assessment
Exhibit 44: Merck Strategy assessment
Exhibit 45: Merck: Opportunity assessment
